EVIA Life Sciences

EVIA Life Sciences is an early-stage biotechnology company pioneering the development of extracellular vesicle (EV) and exosome-based therapeutics derived from its proprietary cell-reprogramming technology. The company's foundational platform chemically reprograms mature hepatocytes into proliferative, non-genetically modified human chemically induced liver progenitor cells (hCLiPs). These progenitor cells serve as a scalable, high-yield source for producing potent EVs containing therapeutic bioactive cargo, such as microRNAs and proteins. EVIA's lead preclinical program focuses on hCLiP-derived extracellular vesicles for the treatment of liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the company's CLiP cell technology is being evaluated in a First-in-Human clinical study for liver regeneration in collaboration with Nagasaki University and Rewind Co., Ltd.